Leptin applications in 2015: what have we learned about leptin and obesity?
Level 5 - mechanism / opinion, no new human data
Narrative review of previous literature without systematic review or original human trial data
PubMed 26313897 · doi:10.1097/MED.0000000000000184
What was done
This narrative review summarized advancements in leptin therapeutics, examining its clinical utility across leptin-deficient states, lipodystrophy, and typical polygenic obesity.
What was found
The abstract reports no numerical data or effect sizes. Qualitatively, leptin therapy reverses morbid obesity caused by congenital leptin deficiency and improves lipodystrophy, leading to regulatory approval in the USA and Japan. Conversely, because typical obesity is characterized by hyperleptinemia and leptin resistance, leptin monotherapy is ineffective for inducing weight loss, though combination approaches and weight maintenance remain under investigation.
Why it matters
It clarifies that leptin administration is therapeutic for rare leptin-deficient conditions and lipodystrophy, but ineffective as a standalone treatment for common obesity.
Limits
The abstract provides no sample sizes, effect estimates, or statistical data. As a narrative review, it lacks systematic search methodology and quantitative meta-analytic synthesis.
Cited by
- supports The hormone leptin was discovered in 1994.